Celldex Therapeutics Earnings
NASDAQ: CLDXHealth CareBiotechnology: In Vitro & In Vivo Diagnostic SubstancesUSD
29.89+0.59 (+2.01%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
After hours: 29.89 0.00%
Celldex Therapeutics earnings summary
In its most recent report on Aug 6, 2026 (Q2 2026), CLDX posted EPS of $-0.94. Revenue for the quarter was $22,000. Across the last 16 reports, CLDX shares moved an average of 6.2% (in either direction) in the first trading session after results, rising 8 times and falling 8 times.
Summary generated from market data by MetaCap's automated system. Methodology
CLDX earnings history
| Report date | EPS est. | EPS actual | Surprise | Price reaction |
|---|---|---|---|---|
| Aug 6, 2026 | — | $-0.94 | — | +0.6% |
| May 7, 2026 | — | $-1.18 | — | -7.7% |
| Feb 25, 2026 | — | $-1.23 | — | -2.2% |
| Nov 10, 2025 | — | $-1.01 | — | +1.4% |
| Aug 7, 2025 | — | $-0.85 | — | +23.4% |
| May 8, 2025 | — | $-0.81 | — | +11.6% |
| Feb 27, 2025 | — | $-0.71 | — | +0.5% |
| Nov 6, 2024 | — | $-0.64 | — | -10.2% |
| Aug 8, 2024 | — | $-0.54 | — | +3.8% |
| May 6, 2024 | — | $-0.56 | — | -4.3% |
| Feb 26, 2024 | — | $-0.84 | — | -7.7% |
| Nov 2, 2023 | — | $-0.81 | — | +3.7% |
| Aug 8, 2023 | — | $-0.65 | — | -0.1% |
| May 4, 2023 | — | $-0.62 | — | +3.2% |
| Feb 28, 2023 | — | $-0.57 | — | -10.6% |
| Nov 9, 2022 | — | $-0.57 | — | -8.0% |
Surprise compares reported EPS with the consensus estimate. Price reaction is the close-to-close move in the first session after the report. Learn about the earnings surprise.